The Lancet

Medications

Budesonide yields durable reduction in eGFR for IgA nephropathy

For patients with immunoglobulin A (IgA) nephropathy, nine months of treatment with targeted-release formulation of budesonide (Nefecon) yields a greater reduction in estimated glomerular filtration rate (eGFR) than placebo, ...

Addiction

Q&A: Bringing addiction care 'inside the house of medicine'

As civilization ground to a halt during the COVID-19 pandemic, trapping humans like caged mice, addiction expert Keith Humphreys could only agonize over the collateral damage. America was already losing the war on addiction ...

page 9 from 40